Cell & Gene Therapies: A Regulatory Update

Return to Insights Center

Related Insights

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Blog

Making cell and gene therapy more accessible in the treatment of solid tumors

Jun 4, 2024

Podcast

CAR-T boxed warnings: What comes next?

Mar 6, 2024

Blog

CAR-T product development: an assessment of FDA’s final guidance for industry

Feb 27, 2024

Blog

Biosimilar reference medicinal product (RMP) regulatory requirements: China, US and EU comparison

Dec 20, 2024

Blog

SITC Crisis in Clinical Research Virtual Summit – Collaborating to Drive Change

Aug 24, 2022

Podcast

Driving change in Cell & Gene Therapies: Key learnings from the SITC Virtual Summit

Sep 19, 2022

Related Insights

Blog

CAR-T boxed warnings: regulatory precedents and opportunities

Feb 9, 2024

Article

Three ways to improve your chances that insurers will pay for a new CGT

Feb 18, 2021

Podcast

Rare endpoints: Delivering on unmet patient needs

May 7, 2024

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Playbook

Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success

Mar 28, 2023

Show more